Pain
Chronic pain is pain lasting beyond normal tissue healing time (often defined as 3 months or more) and affects roughly one in five adults worldwide. It is increasingly understood as a biopsychosocial condition with multiple mechanisms: nociceptive (tissue/inflammatory), neuropathic (nerve injury/dysfunction), and nociplastic/central sensitization (altered pain processing without clear peripheral damage), with many patients exhibiting a mixed picture. Effective care prioritizes function, quality of life, and risk reduction rather than complete pain elimination.
Western medicine emphasizes careful assessment: clarifying pain type, ruling out red flags, gauging functional impact and mental health comorbidities, and avoiding unnecessary imaging. First-line nonpharmacologic strategies include education, graded exercise/physical therapy, cognitive behavioral therapy (CBT) and other psychological therapies, and complementary options such as acupuncture and mindfulness with growing evidence for several pain conditions. Pharmacologic therapy is typically stepped: topical agents and NSAIDs or acetaminophen for nociceptive pain; serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine), tricyclics, and gabapentinoids for neuropathic/nociplastic pain; and muscle relaxants short term if spasm is prominent. Interventional procedures (e.g., joint/soft tissue injections, radiofrequency ablation for facet-mediated pain, neuromodulation in select refractory cases) may help carefully selected patients. Opioids are now used far more judiciously due to limited long-term benefit and substantial risks; guidelines emphasize nonopioid and nonpharmacologic care as the foundation.
Eastern and traditional approaches add modalities with varying supportive evidence. Acupuncture has one of the stronger evidence bases among complementary therapies, showing clinically meaningful but modest benefits for chronic musculoskeletal pain (low back, neck, shoulder), osteoarthritis, and headaches,,
Moderate Evidence
chronic-pain
Fibromyalgia is a chronic, centralized pain syndrome characterized by widespread musculoskeletal pain, fatigue, nonrestorative sleep, cognitive complaints (“fibro fog”), and sensory hypersensitivity. Modern understanding emphasizes central sensitization—an amplified pain processing state with altered pain modulation and increased neural network reactivity. The condition often coexists with mood disorders, irritable bowel syndrome, temporomandibular disorder, headaches, and sleep disturbances, and it disproportionately affects women. Diagnosis is clinical and does not rely on inflammatory or structural abnormalities; laboratory testing is used primarily to exclude other explanations when history or exam suggest them. The 2016 revisions to the American College of Rheumatology (ACR) criteria incorporate a Widespread Pain Index (WPI) and Symptom Severity (SS) scale and require generalized pain in at least four of five regions for at least three months.
Western evidence strongly supports a multimodal approach, with graded exercise (aerobic and resistance training) and patient education as first-line, complemented by cognitive behavioral therapy (CBT) for pain and coping skills, structured sleep management (including CBT for insomnia), and selective use of centrally acting medications. FDA-approved options—duloxetine, milnacipran, and pregabalin—offer modest average benefits for pain and function, while tricyclics (e.g., low-dose amitriptyline) and cyclobenzaprine may improve pain and sleep in some patients. Long-term opioids are discouraged; guidelines favor nonpharmacologic strategies with targeted pharmacotherapy for residual symptoms. EULAR’s management recommendations emphasize individualized, stepped care anchored by exercise and psychoeducation, adding psychological therapies and medications as needed, and considering complementary options with supportive evidence.
Traditional Eastern approaches conceptualize fibromyalgia through functional imbalances. In Chinese
Moderate Evidence
Chronic pain / Rheumatology
Fibromyalgia is a chronic, centralized pain condition characterized by widespread pain, fatigue, nonrestorative sleep, cognitive symptoms (“fibro fog”), and sensory hypersensitivity. Modern understanding emphasizes central sensitization—heightened pain processing in the central nervous system—along with autonomic dysregulation, stress-axis changes, and overlapping conditions (e.g., irritable bowel syndrome, migraine, temporomandibular disorders, and mood and sleep disturbances). Diagnosis is clinical, using validated symptom indices rather than tender-point counts. Management focuses on education, self-management, graded physical activity, psychological therapies, and selected medications. Strong evidence supports aerobic and resistance exercise, cognitive-behavioral therapy (CBT), and mind-body practices. Pharmacotherapy can help a subset of patients but typically yields modest benefits, and guidelines discourage long-term opioid therapy.
Eastern and traditional systems frame fibromyalgia through functional patterns. In Traditional Chinese Medicine (TCM), common patterns include qi and blood stagnation, liver qi constraint, spleen qi deficiency, and kidney yang deficiency, often linked with cold, dampness, and stress. Treatment uses acupuncture (including electroacupuncture), moxibustion, cupping, tuina, and individualized herbal formulas. Evidence for acupuncture is moderate, with several trials and reviews showing short- to medium-term improvements in pain and function, particularly with electroacupuncture. Ayurvedic perspectives often attribute symptoms to vata aggravation and ama (metabolic/toxic) accumulation; therapies include Abhyanga (warm oil massage), Swedana (steam/sudation), Shirodhara, Panchakarma detoxification procedures, and adaptogenic herbs such as Ashwagandha. Clinical evidence in fibromyalgia specifically is limited, though some components (e.g., massage, stress reduction, sleep support) have broader supportive data.
Mind-body practices bridge
Well-Studied
musculoskeletal
Osteoarthritis (OA) is the most common arthritis, driven by age, mechanical loading, prior injury, obesity, and genetics. It features progressive cartilage loss, subchondral bone changes, synovial activation, and periarticular muscle weakness. Patients typically report activity-related joint pain, stiffness (often <30 minutes in the morning), reduced function, and sometimes swelling or crepitus. Knees, hips, hands, and spine are most affected. Diagnosis is clinical, supported by radiographs showing joint-space narrowing, osteophytes, and sclerosis; MRI is rarely required for routine care.
Western management prioritizes nonpharmacologic strategies with the strongest, most consistent benefits across guidelines: education, exercise therapy (aerobic, strengthening, neuromuscular/balance), and weight reduction for those with overweight/obesity. Topical NSAIDs are recommended as first-line pharmacologic therapy for knee and hand OA, with oral NSAIDs used when needed and appropriate. Acetaminophen has diminishing evidence of benefit. Duloxetine can help chronic OA pain, particularly knee OA. Intra-articular corticosteroid injections offer short-term relief; hyaluronic acid remains controversial with mixed evidence. Platelet-rich plasma (PRP) injections are emerging but heterogeneous and not yet guideline-endorsed broadly. Joint replacement is highly effective for end-stage disease.
Eastern and traditional approaches conceptualize OA differently but often converge on movement-based and symptom-relieving therapies. In Traditional Chinese Medicine (TCM), OA commonly maps to Bi syndrome (painful obstruction) with patterns such as wind-cold-damp Bi, blood stasis, and kidney (shen) deficiency. Treatment may include acupuncture (including electroacupuncture and warm-needle techniques), moxibustion, topical herbal liniments (e.g., capsicum), tuina/manual therapy, and herbal formulas (e.g., Du Huo Ji Sheng Tang). Acupuncture for knee OA is among the best-studied TCM applications,
Well-Studied
autoimmune/rheumatologic
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune synovitis that, without timely control, leads to pain, progressive joint damage, disability, and increased cardiovascular risk. Western medicine defines RA by characteristic clinical patterns, serologic autoantibodies, and inflammatory markers, and prioritizes early, aggressive disease modification using a treat‑to‑target strategy. This approach, guided by rigorous randomized trials and international guidelines, has transformed outcomes—many patients can now achieve low disease activity or remission and preserve function.
Diagnosis in Western practice uses ACR/EULAR classification criteria that integrate joint involvement, rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies, acute‑phase reactants (ESR/CRP), and symptom duration. Imaging (ultrasound/MRI) can detect subclinical synovitis and erosions early. Management begins promptly—ideally within weeks of symptom onset—because early window therapy improves long‑term trajectories. First‑line conventional synthetic disease‑modifying antirheumatic drugs (csDMARDs) include methotrexate (anchor), sulfasalazine, hydroxychloroquine, and leflunomide. If targets (remission/low disease activity) are not met, biologic DMARDs (e.g., TNF, IL‑6, T‑cell costimulation, anti‑CD20) or targeted synthetic JAK inhibitors are added or substituted, with iterative monitoring every 1–3 months and shared decision‑making. Short glucocorticoid courses are sometimes used as a bridge, while NSAIDs treat pain but do not alter disease course. Safety monitoring, vaccination, infection screening, and comorbidity risk reduction (e.g., cardiovascular prevention, bone health, smoking cessation, exercise, rehabilitation) are integral.
Eastern and traditional systems conceptualize RA differently but share aims of reducing pain, swelling, and functional limitations while preventing chronic deterioration. Traditional Chinese Medicine (TCM) frames RA within “Bi” (B
Moderate Evidence
